A CFO Departure. A Clinical Miss. A $43 Billion Question Mark. Should You Throw in the Towel on Pfizer Stock?

Pfizer's phase 3 trial for cancer drug sigvotatug vedotin failed, adding pressure to a company already digesting its $43 billion Seagen acquisition and navigating the departure of CFO Dave Denton. The clinical miss removes a potential revenue driver, forcing investors to reassess whether the pharmaceutical giant's pipeline can justify its valuation.

The company retains several bright spots. Weight-loss candidate MET-097i continues through development, targeting a lucrative market. Padcev and Abrysvo, recent launches, are gaining traction commercially. Pfizer also offers a 7.3% dividend yield, providing income while the pipeline matures.

The Seagen deal looms large. At $43 billion, the acquisition represents a major bet on oncology, but integration risks and debt servicing costs create near-term headwinds. With Denton's exit, leadership continuity in managing the balance sheet becomes a question mark during a critical integration period.

The failed cancer trial underscores Pfizer's reliance on its remaining pipeline to offset revenue declines from COVID-19 products. Without sigvotatug vedotin, the company's oncology strategy hinges more heavily on Seagen assets and other candidates.